Analytical Data
-
Gene name
MRTFA
- Application
-
Alternative Names
MKL/myocardin-like protein 1 (Megakaryoblastic leukemia 1 protein) (Megakaryocytic acute leukemia protein)
-
Species
Human
-
Source
E. coli
-
Tag
N- His-KSI
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q969V6
-
Expression Region
400-500aa
-
Molecular Weight
25.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
MRTFA (Myocardin-related transcription factor A) is a member of the MRTF family, crucial in regulating gene expression associated with smooth muscle and cardiac development. It functions as a signaling hub that integrates cues from mechanical stimuli and cytoskeletal dynamics to modulate transcriptional programs, particularly those governing vascular smooth muscle cell contractility and plasticity. Recent studies have highlighted its role in various physiological processes, such as vascular homeostasis and response to injury, as well as its involvement in pathological conditions including hypertension and atherosclerosis. Given its significance, researchers have focused on the biochemical and biophysical characterization of MRTFA, exploring its regulatory mechanisms, post-translational modifications, and interaction with other signaling molecules. The production of recombinant MRTFA proteins for in vitro studies has become a pivotal aspect of this research, enabling a deeper understanding of its functional mechanisms and potential therapeutic targets. By elucidating the structure-function relationships of MRTFA, researchers aim to uncover novel strategies to manipulate its activity for therapeutic benefits, potentially providing new avenues for treating cardiovascular diseases. Thus, the study of MRTFA and its recombinant forms not only contributes to the fundamental knowledge of smooth muscle biology but also holds promise for developing innovative treatments in cardiovascular medicine.
